Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice: clinical research short report

Introduction/Aims In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1-ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access program. In this study we assess neu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Meyer, Thomas (VerfasserIn) , Schumann, Peggy (VerfasserIn) , Weydt, Patrick (VerfasserIn) , Petri, Susanne (VerfasserIn) , Koc, Yasemin (VerfasserIn) , Spittel, Susanne (VerfasserIn) , Bernsen, Sarah (VerfasserIn) , Günther, René (VerfasserIn) , Weishaupt, Jochen H. (VerfasserIn) , Dreger, Marie (VerfasserIn) , Kolzarek, Felix (VerfasserIn) , Kettemann, Dagmar (VerfasserIn) , Norden, Jenny (VerfasserIn) , Boentert, Matthias (VerfasserIn) , Vidovic, Maximilian (VerfasserIn) , Meisel, Christian (VerfasserIn) , Münch, Christoph (VerfasserIn) , Maier, André (VerfasserIn) , Körtvélyessy, Péter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 2023
In: Muscle & nerve
Year: 2023, Jahrgang: 67, Heft: 6, Pages: 515-521
ISSN:1097-4598
DOI:10.1002/mus.27818
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/mus.27818
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27818
Volltext
Verfasserangaben:Thomas Meyer, Peggy Schumann, Patrick Weydt, Susanne Petri, Yasemin Koc, Susanne Spittel, Sarah Bernsen, René Günther, Jochen H. Weishaupt, Marie Dreger, Felix Kolzarek, Dagmar Kettemann, Jenny Norden, Matthias Boentert, Maximilian Vidovic, Christian Meisel, Christoph Münch, André Maier, Péter Körtvélyessy

MARC

LEADER 00000caa a2200000 c 4500
001 1895452457
003 DE-627
005 20241205151901.0
007 cr uuu---uuuuu
008 240715s2023 xx |||||o 00| ||eng c
024 7 |a 10.1002/mus.27818  |2 doi 
035 |a (DE-627)1895452457 
035 |a (DE-599)KXP1895452457 
035 |a (OCoLC)1475302717 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Meyer, Thomas  |d 1967-  |e VerfasserIn  |0 (DE-588)122622065  |0 (DE-627)705974596  |0 (DE-576)293352143  |4 aut 
245 1 0 |a Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS  |b treatment experience in clinical practice: clinical research short report  |c Thomas Meyer, Peggy Schumann, Patrick Weydt, Susanne Petri, Yasemin Koc, Susanne Spittel, Sarah Bernsen, René Günther, Jochen H. Weishaupt, Marie Dreger, Felix Kolzarek, Dagmar Kettemann, Jenny Norden, Matthias Boentert, Maximilian Vidovic, Christian Meisel, Christoph Münch, André Maier, Péter Körtvélyessy 
264 1 |c June 2023 
300 |b Illustrationen 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 16. März 2023 
500 |a Gesehen am 15.07.2024 
520 |a Introduction/Aims In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1-ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access program. In this study we assess neurofilament light chain (NfL) before and during tofersen treatment. Methods In six SOD1-ALS patients treated with tofersen at three specialized ALS centers in Germany, NfL in cerebrospinal fluid (CSF-NfL) and/or serum (sNfL) were investigated using the ALS Functional Rating Scale Revised (ALSFRS-R) and ALS progression rate (ALS-PR), defined by monthly decline of ALSFRS-R. Results Three of the six SOD1-ALS patients reported a negative family history. Three patients harbored a homozygous c.272A > C, p.(Asp91Ala) mutation. These and two other patients showed slower progressing ALS (defined by ALS-PR <0.9), whereas one patient demonstrated rapidly progressing ALS (ALS-PR = 2.66). Mean treatment duration was 6.5 (range 5 to 8) months. In all patients, NfL decreased (mean CSF-NfL: −66%, range −52% to −86%; mean sNfL: −62%, range −36% to −84%). sNfL after 5 months of tofersen treatment was significantly reduced compared with the nearest pretreatment measurement (P = .017). ALS-PR decreased in two patients, whereas no changes in ALSFRS-R were observed in four participants who had very low ALS-PR or ALSFRS-R values before treatment. Discussion In this case series, the significant NfL decline after tofersen treatment confirmed its value as response biomarker in an expanded clinical spectrum of SOD1-ALS. Given the previously reported strong correlation between sNfL and ALS progression, the NfL treatment response supports the notion of tofersen having disease-modifying activity. 
650 4 |a amyotrophic lateral sclerosis 
650 4 |a neurofilament light chain 
650 4 |a tofersen 
700 1 |a Schumann, Peggy  |e VerfasserIn  |4 aut 
700 1 |a Weydt, Patrick  |e VerfasserIn  |4 aut 
700 1 |a Petri, Susanne  |e VerfasserIn  |4 aut 
700 1 |a Koc, Yasemin  |e VerfasserIn  |4 aut 
700 1 |a Spittel, Susanne  |e VerfasserIn  |0 (DE-588)1252765576  |0 (DE-627)1794401423  |4 aut 
700 1 |a Bernsen, Sarah  |e VerfasserIn  |4 aut 
700 1 |a Günther, René  |e VerfasserIn  |4 aut 
700 1 |a Weishaupt, Jochen H.  |d 1971-  |e VerfasserIn  |0 (DE-588)122148924  |0 (DE-627)705789039  |0 (DE-576)293117810  |4 aut 
700 1 |a Dreger, Marie  |e VerfasserIn  |4 aut 
700 1 |a Kolzarek, Felix  |e VerfasserIn  |4 aut 
700 1 |a Kettemann, Dagmar  |e VerfasserIn  |0 (DE-588)1167602706  |0 (DE-627)1031197184  |0 (DE-576)511211643  |4 aut 
700 1 |a Norden, Jenny  |e VerfasserIn  |4 aut 
700 1 |a Boentert, Matthias  |e VerfasserIn  |4 aut 
700 1 |a Vidovic, Maximilian  |e VerfasserIn  |4 aut 
700 1 |a Meisel, Christian  |e VerfasserIn  |4 aut 
700 1 |a Münch, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Maier, André  |e VerfasserIn  |4 aut 
700 1 |a Körtvélyessy, Péter  |d 1977-  |e VerfasserIn  |0 (DE-588)1042157146  |0 (DE-627)768240603  |0 (DE-576)393716511  |4 aut 
773 0 8 |i Enthalten in  |t Muscle & nerve  |d New York, NY [u.a.] : Wiley, 1978  |g 67(2023), 6 vom: Juni, Seite 515-521  |h Online-Ressource  |w (DE-627)270128891  |w (DE-600)1476641-3  |w (DE-576)079876161  |x 1097-4598  |7 nnas  |a Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS treatment experience in clinical practice: clinical research short report 
773 1 8 |g volume:67  |g year:2023  |g number:6  |g month:06  |g pages:515-521  |g extent:7  |a Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS treatment experience in clinical practice: clinical research short report 
856 4 0 |u https://doi.org/10.1002/mus.27818  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.27818  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240715 
993 |a Article 
994 |a 2023 
998 |g 122148924  |a Weishaupt, Jochen H.  |m 122148924:Weishaupt, Jochen H.  |d 60000  |d 62700  |e 60000PW122148924  |e 62700PW122148924  |k 0/60000/  |k 1/60000/62700/  |p 9 
999 |a KXP-PPN1895452457  |e 4551225851 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"titleAlt":[{"title":"Muscle and nerve"}],"note":["Gesehen am 28.02.08"],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1978 -"],"language":["eng"],"title":[{"subtitle":"official journal of the American Association of Electrodiagnostic Medicine","title":"Muscle & nerve","title_sort":"Muscle & nerve"}],"recId":"270128891","disp":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS treatment experience in clinical practice: clinical research short reportMuscle & nerve","origin":[{"publisherPlace":"New York, NY [u.a.]","dateIssuedDisp":"1978-","dateIssuedKey":"1978","publisher":"Wiley"}],"id":{"doi":["10.1002/(ISSN)1097-4598"],"eki":["270128891"],"issn":["1097-4598"],"zdb":["1476641-3"]},"part":{"pages":"515-521","volume":"67","text":"67(2023), 6 vom: Juni, Seite 515-521","extent":"7","issue":"6","year":"2023"}}],"note":["Online veröffentlicht: 16. März 2023","Gesehen am 15.07.2024"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"June 2023"}],"id":{"eki":["1895452457"],"doi":["10.1002/mus.27818"]},"recId":"1895452457","name":{"displayForm":["Thomas Meyer, Peggy Schumann, Patrick Weydt, Susanne Petri, Yasemin Koc, Susanne Spittel, Sarah Bernsen, René Günther, Jochen H. Weishaupt, Marie Dreger, Felix Kolzarek, Dagmar Kettemann, Jenny Norden, Matthias Boentert, Maximilian Vidovic, Christian Meisel, Christoph Münch, André Maier, Péter Körtvélyessy"]},"title":[{"title_sort":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS","subtitle":"treatment experience in clinical practice: clinical research short report","title":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS"}],"person":[{"display":"Meyer, Thomas","given":"Thomas","role":"aut","family":"Meyer"},{"given":"Peggy","role":"aut","family":"Schumann","display":"Schumann, Peggy"},{"display":"Weydt, Patrick","role":"aut","given":"Patrick","family":"Weydt"},{"role":"aut","given":"Susanne","family":"Petri","display":"Petri, Susanne"},{"display":"Koc, Yasemin","family":"Koc","role":"aut","given":"Yasemin"},{"display":"Spittel, Susanne","family":"Spittel","role":"aut","given":"Susanne"},{"given":"Sarah","role":"aut","family":"Bernsen","display":"Bernsen, Sarah"},{"display":"Günther, René","given":"René","role":"aut","family":"Günther"},{"display":"Weishaupt, Jochen H.","given":"Jochen H.","role":"aut","family":"Weishaupt"},{"display":"Dreger, Marie","given":"Marie","role":"aut","family":"Dreger"},{"family":"Kolzarek","role":"aut","given":"Felix","display":"Kolzarek, Felix"},{"display":"Kettemann, Dagmar","role":"aut","given":"Dagmar","family":"Kettemann"},{"display":"Norden, Jenny","given":"Jenny","role":"aut","family":"Norden"},{"role":"aut","given":"Matthias","family":"Boentert","display":"Boentert, Matthias"},{"family":"Vidovic","role":"aut","given":"Maximilian","display":"Vidovic, Maximilian"},{"role":"aut","given":"Christian","family":"Meisel","display":"Meisel, Christian"},{"role":"aut","given":"Christoph","family":"Münch","display":"Münch, Christoph"},{"role":"aut","given":"André","family":"Maier","display":"Maier, André"},{"given":"Péter","role":"aut","family":"Körtvélyessy","display":"Körtvélyessy, Péter"}],"language":["eng"],"physDesc":[{"extent":"7 S.","noteIll":"Illustrationen"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} 
SRT |a MEYERTHOMANEUROFILAM2023